

**Summary of Consolidated Financial Results [IFRS]
for the First Six Months of the Fiscal Year Ending March 31, 2018**

November 8, 2017

Listed company name : Sysmex Corporation
Code : 6869
Listed stock exchanges : Tokyo Stock Exchange
URL : <http://www.sysmex.co.jp>
Company representative : Hisashi Ietsugu, Chairman and CEO
Contact : Hiroshi Nagao, Executive Officer,
Corporate Business Administration
Phone : 078(265)-0500
Scheduled date for filing of quarterly report : November 13, 2017
Scheduled date for dividend payment : December 4, 2017
Preparation of supplementary material for
quarterly earnings : Yes
Holding of earnings announcement : Yes

(Unit: Millions of Yen)

1. Results for the First Six Months of the Fiscal Year Ending March 31, 2018

(1) Operating results

(% changes as compared with the corresponding period of the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit	
Six months ended Sep. 30, 2017	131,107	10.4%	28,006	3.6%	27,548	10.0%	19,038	(18.7)%
Six months ended Sep. 30, 2016	118,799	(2.4)%	27,030	(9.0)%	25,041	(11.9)%	23,407	26.8%

	Profit attributable to owners of the parent		Total comprehensive income		Basic earnings per share (Yen)	Diluted earnings per share (Yen)
Six months ended Sep. 30, 2017	19,193	(18.3)%	25,249	85.7%	92.18	91.96
Six months ended Sep. 30, 2016	23,484	27.2%	13,600	(26.2)%	112.90	112.54

(2) Financial condition

	Total assets	Total equity	Equity attributable to owners of the parent	Equity attributable to owners of the parent to total assets
As of Sep. 30, 2017	306,773	229,477	228,793	74.6%
As of Mar. 31, 2017	279,817	210,252	209,406	74.8%

2. Dividend

	Dividend per share				
	First quarter (Yen)	Second quarter (Yen)	Third quarter (Yen)	Year-end (Yen)	Annual (Yen)
Year ended Mar. 31, 2017	—	28.00	—	30.00	58.00
Year ending Mar. 31, 2018	—	30.00			
Year ending Mar. 31, 2018 (Forecast)			—	30.00	60.00

Note: Revision of dividends forecast for this period: No

3. Financial Forecast for the Year Ending March 31, 2018

(% changes as compared with the corresponding period of the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit attributable to owners of the parent		Basic earnings per share (Yen)
Year ending Mar. 31, 2018	280,000	12.0%	58,000	12.2%	58,000	18.5%	41,500	2.1%	199.29

Note: Revision of business forecast for this period: Yes

4. Other Information

- (1) Changes in significant consolidated subsidiaries (which resulted in changes in scope of consolidation):
No
- (2) Changes in accounting policies and accounting estimates
 - 1) Changes in accounting policies required by IFRS: No
 - 2) Other changes in accounting policies: No
 - 3) Changes in accounting estimates: No
- (3) Number of outstanding stock (common stock)
 - 1) Number of outstanding stock at the end of each fiscal period (including treasury stock):
208,708,432 shares as of Sep. 30, 2017; 208,631,032 shares as of Mar. 31, 2017
 - 2) Number of treasury stock at the end of each fiscal period:
444,876 shares as of Sep. 30, 2017; 444,556 shares as of Mar. 31, 2017
 - 3) Average number of outstanding stock for each period (cumulative):
208,221,530 shares for the six months ended Sep. 30, 2017
208,014,453 shares for the six months ended Sep. 30, 2016

Note: Quarterly summaries of financial results are excluded from quarterly reviews.

* Explanation regarding the appropriate use of financial forecast and other information

1. The forecasts and future projections contained herein have been prepared on the basis of rational decisions given the information available as of the date of announcement of this document. These forecasts do not represent a commitment by the Company, and actual performance may differ substantially from forecasts for a variety of reasons. Please refer to “3) Consolidated financial forecast” within “1. Financial Performance” on page 5 of the attachment to this document for cautionary statements concerning the conditions and performance forecasts that serve as the basis for these forecasts.
2. Supplementary financial materials (in Japanese and English) will be posted on the Sysmex website on Wednesday, November 8, 2017.

Content of Supplementary Materials

1. Financial performance	2
1) Performance analysis	2
2) Financial conditions analysis	5
3) Consolidated financial forecast	5
2. Condensed quarterly consolidated financial statements and notes	6
1) Condensed quarterly consolidated statement of financial position	6
2) Condensed quarterly consolidated statement of income	8
3) Condensed quarterly consolidated statement of other comprehensive income	9
4) Condensed quarterly consolidated statement of changes in equity	10
5) Condensed quarterly consolidated statement of cash flows	11
6) Notes to the condensed quarterly consolidated financial statements	12
1. Notes related to the going concern assumption	12
2. Segment information	12

1. Financial performance

1) Performance analysis

Future-related information contained in the text below is based on the judgement of the Sysmex Group (Sysmex Corporation and its affiliated companies) as of the end of the fiscal period under review.

During the first six months of the fiscal year ending March 31, 2018, the Japanese economy continued to recover, buoyed by rebounds in personal consumption and capital investment. Overall, the overseas economy also continued its modest recovery.

On the healthcare front, the Japanese government is including the medical and healthcare industry in its growth strategies, which is expected to continue invigorating healthcare-related industries going forward. In the United States, the Affordable Care Act that was introduced to decrease the number of people without medical insurance is being reviewed. In China, the country is also introducing policies to curtail medical expenses, but overseas the foundations of healthcare-related demand remain solid.

Under these conditions, Sysmex acquired the shares of Oxford Gene Technology IP Limited (“OGT”) and converted the company to a subsidiary. In the cytogenetics market, we plan to reinforce our technology base for genomic medicine by fusing Sysmex’s flow FISH¹ and other automation technologies with OGT’s capabilities in the development of high-quality reagents.

To reinforce its R&D related to information analysis technology, centered on bioinformatics², Sysmex established a new R&D facility, the Skyfront Research Campus, within the Life Innovation Center, located within the Kawasaki INnovation Gateway at SKYFRONT³, in the Tonomachi area of Kawasaki, Kanagawa Prefecture. This area is home to a cluster of leading-edge life science companies and research institutions. In establishing an R&D facility there, Sysmex aims to facilitate collaboration with R&D institutions, universities and companies in the Kanto area.

The RIKEN GENESIS Innovation Genome Center of RIKEN GENESIS Co., Ltd., a Sysmex subsidiary, is located in the same center. We will employ next-generation sequencers⁴ and cutting-edge gene analyzers for liquid biopsy⁵, to provide gene analysis service and to perform clinical sequence testing⁶ to quality levels based on international quality standards, thereby contributing to the promotion of genomic medicine.

We completed the expansion of our reagent factory in the United States. This move was aimed at responding to future increases in reagent demand in the Americas, as well as ensuring a stable supply of reagents from a medium- to long-term perspective. As a result, production capacity is now at 1.8 times the previous level. The Sysmex Group manufactures reagents at two locations in Japan and seven locations in six other countries. We will continue to provide a stable supply of products through a production structure that is in line with market environments in various regions.

1 Flow FISH:

Whereas FISH testing requires evaluation of slides under a microscope, flow FISH testing uses an imaging flow cytometer to capture images, enabling automated analysis. FISH testing uses fluorescent material binding only specific genes to detect target genes within a chromosome.

2 Bioinformatics:

Information technology that analyzes genetic and protein information to explain Biological function and phenotype; in particular, signifying the technology for analyzing relationships between genetic information and disease.

3 Kawasaki INnovation Gateway at SKYFRONT:

An open innovation hub located within the Life Innovation in Keihin Coastal Areas International Strategy Comprehensive Special Zone, where companies involved in the life sciences gather. Based on national government growth strategy, the hub is eligible for support, including the easing of regulations, with a view to establishing innovative business models.

4 Next-generation sequencer (NGS):

An analyzer for reading the huge volumes of genetic information contained in DNA bases and sequences.

5 Liquid biopsy:

Detection of cancer or other diseases by testing bodily fluids such as blood. This type of testing is less invasive than conventional physical biopsies.

6 Clinical sequence testing:

The type of testing which analyzes genetic information of patients with a high degree of precision by using the next-generation sequencer with the purpose of diagnosis and treatment methods selection.

Net sales by destination

	Six months ended September 30, 2016		Six months ended September 30, 2017		YoY (Previous period = 100)
	Amount (Millions of yen)	Percentage of total (%)	Amount (Millions of yen)	Percentage of total (%)	
Japan	21,006	17.7	21,156	16.1	100.7
Americas	27,804	23.4	30,180	23.0	108.5
EMEA	31,769	26.7	34,210	26.1	107.7
China	28,412	23.9	34,079	26.0	119.9
Asia Pacific	9,807	8.3	11,480	8.8	117.1
Overseas subtotal	97,793	82.3	109,951	83.9	112.4
Total	118,799	100.0	131,107	100.0	110.4

In Japan, instrument sales decreased, mainly in the hematology field. However, sales of reagents were firm, centered on the hemostasis and immunochemistry fields. As a result, sales in Japan rose 0.7% year on year, to ¥21,156 million.

In overseas markets, instrument sales were down, mainly in the hemostasis field, but reagent sales grew in the hematology and hemostasis fields. Consequently, overseas sales increased 12.4% year on year, to ¥109,951 million. The overseas sales ratio rose 1.6 percentage points, to 83.9%.

As a result, during the first six months of the year the Group recorded consolidated net sales of ¥131,107 million, up 10.4% year on year. Operating profit rose 3.6%, to ¥28,006 million; profit before tax grew 10.0%, to ¥27,548 million; and profit attributable to owners of the parent declined 18.3%, to ¥19,193 million.

Performance by segment

(1) Japan

Sales of reagents increased in Japan, mainly in the hemostasis and immunochemistry fields, but export sales decreased. Sales in this segment consequently rose 0.1% year on year, to ¥22,312 million.

On the profit front, higher sales, including intragroup exports, had a positive impact, and efforts to curtail SG&A expenses outpaced the rise in cost of sales. These and other factors led to a 9.7% rise in segment profit (operating profit), to ¥19,337 million.

(2) Americas

Sales rose in the United States, pushed up by higher sales of reagents due to growth in the installed instrument base, although sales of instruments fell in the hematology and hemostasis fields. In Central and South America, sales fell on a local currency basis, reflecting the acquisition of government projects in Mexico in the corresponding period of the previous fiscal year. Overall, sales in the Americas grew 8.7% year on year, to ¥28,617 million.

Segment profit (operating profit) grew 67.9%, to ¥2,921 million, thanks to higher sales and such factors as lower payments of Group trademark royalties.

(3) EMEA

Sales of instruments declined, mainly in the hematology and hemostasis fields, but reagent sales rose due to expansion of the installed instrument base, causing sales to grow 8.4% year on

year, to ¥34,713 million.

Although SG&A expenses increased, as we worked to reinforce our sales structure, the impact of higher sales and an improved cost of sales ratio prompted an 8.8% year-on-year rise in segment profit (operating profit), to ¥2,784 million.

(4) China

Despite lower instrument sales in the hemostasis field, reagent sales grew in the hematology and hemostasis fields, pushing up sales 19.9% year on year, to ¥34,047 million.

In addition to the effect of higher sales, the cost of sales ratio improved due to a revision in intragroup transaction prices. Segment profit (operating profit) expanded 145.6%, to ¥3,683 million.

(5) Asia Pacific

Sales grew in Southeast Asia, centered on the hematology field. In South Asia, sales expanded in India and Bangladesh in the hematology and hemostasis fields. In Australia, performance reflected sales to large-scale commercial labs in the corresponding period of the previous fiscal year. However, sales rose in South Korea and Taiwan, pushing sales in the region up 17.1% year on year, to ¥11,416 million.

Although SG&A expenses increased, segment profit (operating profit) grew 9.7% year on year, to ¥1,145 million, due to the effect of higher sales, which pushed up gross profit.

2) Financial conditions analysis

(1) Assets, liabilities and equity

As of September 30, 2017, total assets amounted to ¥306,773 million, up ¥26,956 million from March 31, 2017. As principal factors, despite a ¥2,875 million decrease in cash and cash equivalents, inventories rose ¥7,953 million, intangible assets expanded ¥7,022 million, goodwill increased ¥4,445 million, trade and other receivables (current assets) expanded ¥3,780 million, and property, plant and equipment grew ¥2,553 million.

Meanwhile, total liabilities as of September 30, 2017, were ¥77,296 million, up ¥7,731 million from their level on March 31, 2017. Principal factors included increases of ¥3,790 million in income taxes payable, of ¥1,969 million in trade and other payables, and of ¥1,462 million in other short-term financial liabilities.

Total equity came to ¥229,477 million, up ¥19,224 million from March 31, 2017. Among principal reasons, retained earnings rose ¥12,947 million, and other components of equity increased ¥6,211 million. Equity attributable to owners of the parent to total assets as of September 30, 2017, was 74.6%, down 0.2 percentage point from the 74.8% recorded as of March 31, 2017.

(2) Cash flows

As of September 30, 2017, cash and cash equivalents amounted to ¥55,068 million, down ¥2,875 million from March 31, 2017.

Cash flows from various activities during the first six months of the fiscal year are described in more detail below.

(Cash flows from operating activities)

Net cash provided by operating activities was ¥23,638 million, up ¥8,780 million from the first six months of the preceding fiscal year. As principal factors, profit before tax provided ¥27,548 million (¥2,507 million more than in the corresponding period of the preceding year), depreciation and amortization provided ¥7,142 million (up ¥1,391 million), an increase in trade receivables used ¥890 million (provided ¥940 million in the first six months of the previous year), an increase in inventories used ¥4,866 million (up ¥1,825 million), an increase in trade payables provided ¥3,218 million (used ¥2,768 million in the first six months of the previous year), a decrease in advance received used ¥120 million (down ¥1,199 million), and income taxes paid used ¥5,309 million (down ¥2,993 million).

(Cash flows from investing activities)

Net cash used in investing activities was ¥21,746 million (up ¥12,463 million). Among major factors, purchase of property, plant and equipment used ¥5,563 million (down ¥595 million from the corresponding period of the previous fiscal year), purchase of intangible assets used ¥4,794 million (up ¥1,801 million), purchase of investments in equity instruments used ¥1,715 million (up ¥1,085 million) and acquisitions of subsidiaries or other businesses used ¥9,469 million (up ¥8,016 million).

(Cash flows from financing activities)

Net cash used in financing activities was ¥6,110 million (up ¥744 million). This was mainly due to dividends paid of ¥6,245 million (up ¥424 million).

3) Consolidated financial forecast

For the Company's consolidated financial forecast for the full fiscal year, please refer to the Announcement Regarding Revision of Full-Year Financial Results Forecast for the Fiscal Year Ending March 31, 2018, announced today (November 8, 2017).

2. Condensed quarterly consolidated financial statements and notes

1) Condensed quarterly consolidated statement of financial position

(Unit: Millions of yen)

	As of March 31, 2017	As of September 30, 2017
Assets		
Current assets		
Cash and cash equivalents	57,944	55,068
Trade and other receivables	63,084	66,865
Inventories	36,998	44,951
Other short-term financial assets	528	309
Income taxes receivable	457	534
Other current assets	7,303	7,457
Total current assets	<u>166,318</u>	<u>175,187</u>
Non-current assets		
Property, plant and equipment	60,144	62,698
Goodwill	8,308	12,754
Intangible assets	21,228	28,250
Investments accounted for using the equity method	552	1,477
Trade and other receivables	8,813	9,828
Other long-term financial assets	6,107	7,096
Asset for retirement benefits	666	652
Other non-current assets	2,095	2,167
Deferred tax assets	5,581	6,660
Total non-current assets	<u>113,499</u>	<u>131,586</u>
Total assets	<u>279,817</u>	<u>306,773</u>

(Unit: Millions of yen)

	As of March 31, 2017	As of September 30, 2017
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	24,376	26,345
Other short-term financial liabilities	956	2,419
Income taxes payable	2,915	6,706
Provisions	610	615
Advance received	6,418	6,553
Accrued expenses	8,330	9,358
Accrued bonuses	6,636	6,021
Other current liabilities	9,708	9,034
Total current liabilities	<u>59,952</u>	<u>67,053</u>
Non-current liabilities		
Long-term financial liabilities	549	468
Liability for retirement benefits	654	709
Provisions	2,318	2,269
Other non-current liabilities	3,527	2,835
Deferred tax liabilities	2,562	3,959
Total non-current liabilities	<u>9,612</u>	<u>10,242</u>
Total liabilities	<u>69,564</u>	<u>77,296</u>
Equity		
Equity attributable to owners of the parent		
Capital stock	11,611	11,766
Capital surplus	17,303	17,378
Retained earnings	188,506	201,454
Treasury stock	(289)	(291)
Other components of equity	(7,725)	(1,514)
Total equity attributable to owners of the parent	<u>209,406</u>	<u>228,793</u>
Non-controlling interests	<u>845</u>	<u>684</u>
Total equity	<u>210,252</u>	<u>229,477</u>
Total liabilities and equity	<u>279,817</u>	<u>306,773</u>

2) Condensed quarterly consolidated statement of income

(Unit: Millions of yen)

	Six months ended September 30, 2016	Six months ended September 30, 2017
Net sales	118,799	131,107
Cost of sales	48,894	56,597
Gross profit	69,905	74,510
Selling, general and administrative expenses	36,423	38,981
Research and development expenses	7,284	7,678
Other operating income	975	228
Other operating expenses	142	71
Operating profit	27,030	28,006
Financial income	315	135
Financial expenses	78	118
Share of profit (loss) on equity method	(265)	(275)
Foreign exchange gain (loss)	(1,961)	(198)
Profit before tax	25,041	27,548
Income tax expenses	1,633	8,510
Profit	23,407	19,038
Profit attributable to		
Owners of the parent	23,484	19,193
Non-controlling interests	(76)	(155)
Profit	23,407	19,038
		(Unit: Yen)
Earnings per share		
Basic	112.90	92.18
Diluted	112.54	91.96

3) Condensed quarterly consolidated statement of other comprehensive income

(Unit: Millions of yen)

	Six months ended September 30, 2016	Six months ended September 30, 2017
Profit	23,407	19,038
Other comprehensive income		
Items that will not be reclassified subsequently to profit or loss		
Net gain (loss) on financial assets measured at fair value through other comprehensive income	(91)	239
Total	(91)	239
Items that may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	(9,707)	5,972
Share of other comprehensive income of investments accounted for using the equity method	(8)	0
Total	(9,715)	5,972
Total other comprehensive income	(9,807)	6,211
Comprehensive income	13,600	25,249
Comprehensive income attributable to		
Owners of the parent	13,676	25,404
Non-controlling interests	(76)	(155)
Comprehensive income	13,600	25,249

4) Condensed quarterly consolidated statement of changes in equity
Six months ended September 30, 2016

(Unit: Millions of yen)

	Equity attributable to owners of the parent					Total	Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity			
As of April 1, 2016	11,016	16,969	159,375	(285)	(4,275)	182,800	0	182,801
Profit			23,484			23,484	(76)	23,407
Other comprehensive income					(9,807)	(9,807)	(0)	(9,807)
Comprehensive income	—	—	23,484	—	(9,807)	13,676	(76)	13,600
Exercise of warrants	357	200				558		558
Cash dividends			(5,820)			(5,820)		(5,820)
Purchase of treasury stock				(0)		(0)		(0)
Transfer to retained earnings			1		(1)	—		—
Changes from business combination						—	1,028	1,028
Equity transactions with non-controlling interests		—				—	—	—
Total transactions with the owners	357	200	(5,819)	(0)	(1)	(5,263)	1,028	(4,234)
As of September 30, 2016	11,374	17,170	177,040	(286)	(14,084)	191,214	952	192,167

Six months ended September 30, 2017

(Unit: Millions of yen)

	Equity attributable to owners of the parent					Total	Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity			
As of April 1, 2017	11,611	17,303	188,506	(289)	(7,725)	209,406	845	210,252
Profit			19,193			19,193	(155)	19,038
Other comprehensive income					6,211	6,211	0	6,211
Comprehensive income	—	—	19,193	—	6,211	25,404	(155)	25,249
Exercise of warrants	154	86				240		240
Cash dividends			(6,245)			(6,245)		(6,245)
Purchase of treasury stock				(2)		(2)		(2)
Transfer to retained earnings			—		—	—		—
Changes from business combination						—	—	—
Equity transactions with non-controlling interests		(11)				(11)	(6)	(18)
Total transactions with the owners	154	74	(6,245)	(2)	—	(6,018)	(6)	(6,025)
As of September 30, 2017	11,766	17,378	201,454	(291)	(1,514)	228,793	684	229,477

5) Condensed quarterly consolidated statement of cash flows

(Unit: Millions of yen)

	Six months ended September 30, 2016	Six months ended September 30, 2017
Cash flows from operating activities		
Profit before tax	25,041	27,548
Depreciation and amortization	5,751	7,142
Decrease (increase) in trade receivables	940	(890)
Decrease (increase) in inventories	(3,040)	(4,866)
Increase (decrease) in trade payables	(2,768)	3,218
Decrease/increase in consumption taxes receivable/payable	2,200	1,093
Increase (decrease) in accounts payable– other	(1,329)	(866)
Increase (decrease) in advance received	(1,319)	(120)
Increase (decrease) in accrued bonuses	(1,442)	(768)
Other–net	(1,068)	(2,622)
Subtotal	22,965	28,868
Interest and dividend received	238	120
Interest paid	(43)	(40)
Income taxes paid	(8,303)	(5,309)
Net cash provided by (used in) operating activities	14,857	23,638
Cash flows from investing activities		
Purchase of property, plant and equipment	(6,159)	(5,563)
Purchase of intangible assets	(2,993)	(4,794)
Purchase of investments in equity instruments	(629)	(1,715)
Acquisitions of subsidiaries or other businesses	(1,453)	(9,469)
Net decrease (increase) in short-term loans receivable	1,930	–
Other–net	22	(202)
Net cash provided by (used in) investing activities	(9,282)	(21,746)
Cash flows from financing activities		
Dividends paid	(5,820)	(6,245)
Other–net	454	134
Net cash provided by (used in) financing activities	(5,366)	(6,110)
Foreign currency translation adjustments on cash and cash equivalents	(3,012)	1,342
Net increase (decrease) in cash and cash equivalents	(2,803)	(2,875)
Cash and cash equivalents, beginning of term	56,481	57,944
Cash and cash equivalents, end of term	53,678	55,068

6) Notes to the condensed quarterly consolidated financial statements

1. Notes related to the going concern assumption

Not applicable

2. Segment information

1) Overview of reportable segments

The Group's reportable segments are the business units of the Group for which discrete financial information is available and whose operating results are regularly reviewed by the Managing Board to make decisions about resources to be allocated to the segment and assess its performance.

The Group is primarily engaged in the manufacture and sale of diagnostic instruments and reagents. These businesses are conducted in Japan by the Company, and in the Americas, EMEA, China and the Asia Pacific by regional headquarters established in those regions. These companies formulate comprehensive strategies tailored to regional characteristics and conduct business activities accordingly. Regional headquarters and other domestic and overseas subsidiaries are independent management units that handle production and sales for each region.

Accordingly, the Group has five reportable segments comprising geographical segments based on manufacturing and sales systems. These are "Japan," the "Americas," "EMEA," "China," and the "Asia Pacific."

2) Segment profit and operating results

Profit and operating results from continuing operations by reportable segment of the Group are as follows:

Intersegment sales are determined based on market prices or costs of goods manufactured.

Accounting policies of reporting segments are consistent with the Group's accounting policies indicated in the consolidated financial statements for the previous fiscal year.

Six months ended September 30, 2016

(Unit: Millions of yen)

	Reportable segment						Adjustments (Note 1)	Consolidated (Note 2)
	Japan	Americas	EMEA	China	Asia Pacific	Total		
Sales								
Sales to external customers	22,301	26,335	32,009	28,405	9,747	118,799	—	118,799
Intersegment sales	45,929	172	1,468	2	2	47,575	(47,575)	—
Total	68,231	26,507	33,477	28,408	9,749	166,374	(47,575)	118,799
Segment profit	17,632	1,740	2,559	1,499	1,044	24,476	2,554	27,030
Financial income	—	—	—	—	—	—	—	315
Financial expenses	—	—	—	—	—	—	—	78
Share of profit (loss) on equity method	—	—	—	—	—	—	—	(265)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	(1,961)
Profit before tax	—	—	—	—	—	—	—	25,041
Income tax expenses	—	—	—	—	—	—	—	1,633
Profit	—	—	—	—	—	—	—	23,407

Notes:

1. Segment profit adjustments of ¥2,554 million include ¥2 million for the elimination of intersegment transactions, ¥2,556 million for the unrealized gains on inventories, and negative ¥4 million for the unrealized gains on non-current assets.
2. Segment profit is reconciled with operating profit in the condensed quarterly consolidated statement of income.

Six months ended September 30, 2017

(Unit: Millions of yen)

	Reportable segment						Adjustments (Note 1)	Consolidated (Note 2)
	Japan	Americas	EMEA	China	Asia Pacific	Total		
Sales								
Sales to external customers	22,312	28,617	34,713	34,047	11,416	131,107	—	131,107
Intersegment sales	49,693	187	1,134	11	2	51,029	(51,029)	—
Total	72,006	28,804	35,847	34,059	11,418	182,137	(51,029)	131,107
Segment profit	19,337	2,921	2,784	3,683	1,145	29,872	(1,865)	28,006
Financial income	—	—	—	—	—	—	—	135
Financial expenses	—	—	—	—	—	—	—	118
Share of profit (loss) on equity method	—	—	—	—	—	—	—	(275)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	(198)
Profit before tax	—	—	—	—	—	—	—	27,548
Income tax expenses	—	—	—	—	—	—	—	8,510
Profit	—	—	—	—	—	—	—	19,038

Notes:

1. Segment profit adjustments of negative ¥1,865 million include negative ¥4 million for the elimination of intersegment transactions, negative ¥1,902 million for the unrealized gains on inventories, and ¥45 million for the unrealized gains on non-current assets.
2. Segment profit is reconciled with operating profit in the condensed quarterly consolidated statement of income.